From Hypothesis to Human Data: Koralo’s Mission to Reinvent Everyday Foods Through Gut Health

Koralo is currently enrolled in the Alethios Early Stage Program, running a structured human study to validate its gut health innovations. For cofounder Guido Albanese, building products rooted in measurable impact wasn’t optional — it was foundational. In this conversation, he shares Koralo’s mission, what it takes to launch a clinical study as an early-stage team, and why human evidence is central to earning both consumer and investor trust.

1. Briefly describe Koralo's mission and the human health problem you’re working to solve.

Guido:
Eat good, look good, feel good. Our mission is to help people improve their wellbeing through gut health by transforming everyday foods into natural health boosts. We believe functional nutrition shouldn’t feel clinical or complicated — it should integrate seamlessly into daily life.

2. When you think about building trust in a health product, what role does human evidence play for you?

Guido:
We are a data-driven start-up. Human clinical evidence helps us identify where we can truly make a difference in people’s lives and shape our product applications accordingly to have the maximum positive impact. Conviction alone isn’t enough — measurable outcomes matter.

3. What has it been like to get a structured study up and running as an early-stage team?

Guido:
Challenging, fun, and exciting. Challenging because the approach was totally new for us. Fun because we learned a lot along the way. And exciting to see our hypothesis coming to life with real data backing it. Running a study transforms abstract ideas into something tangible.

4. What made Alethios feel like the right partner to support this study?

Guido:
Alethios was there all the way helping us navigate — from the regulatory framework of running a clinical study to their critical thinking and practical advice on how to design a study that fit the stage we are at. That balance between rigor and flexibility was key for us.

5. What have you appreciated about not needing traditional clinical infrastructure to run this study?

Guido:
First, the ease and speed of setting up the study — we could focus on content rather than process. More importantly, it allowed us to place our product in a natural environment, where it blended into the daily lives of participants. That reflects real-world performance much better than a traditional, artificial setting.

6. What would you tell another early-stage health founder who’s considering running their first human study?

Guido:
Get a partner like Alethios — someone who understands the challenges of a start-up and helps you hands-on by adjusting to your processes rather than forcing you into theirs. Early-stage teams need infrastructure that adapts to them, not bureaucracy that slows them down.

7. How could this study help with funding for the company in the future?

Guido:
Today’s food world is full of empty promises. We strongly believe clinical-based evidence doesn’t only build trust with consumers — it builds trust with investors as well. Data strengthens credibility, and credibility strengthens long-term growth.

That perspective captures a core principle of the Early Stage Program, If you’re an entrepreneur, researcher, or innovator in human health—and you’re ready to run a real study—we’d love to hear from you.

Apply to the Alethios Early stage Program

‍